tirzepatide substitute F.D.A. Approves New Obesity Drug That Will Compete With Wegovy Exploring Alternatives: What Can Replace

Orforglipron efficacy According to the phase 3 ATTAIN1 clinical trial, people with obesity and overweight (without diabetes) who used the highest dose (36 mg) of orforglipron (an oral glucagon-like peptide1 receptor agonist) lost approximately 12.4% of body weight after 72 weeks

Two injectable medications we may recommend for eligible patients are Mounjaro and Ozempic

doi: 10.3389/fpsyt.2023.1238353

Additional articles were located through citation chaining by examining the reference list of selected studies

You should also read the full Prescribing Information and Medication Guide that comes with your prescription each time it is filled

On rest days, return to your standard calorie target